Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Di Cosimo, Torri, and Porcu.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, deGregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C. Trapp E, et al. J Natl Cancer Inst. 2019 Nov 1;111(11):1234-1235. doi: 10.1093/jnci/djz095. J Natl Cancer Inst. 2019. PMID: 31187135 Free PMC article. No abstract available.
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Trapp E, et al. J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152. J Natl Cancer Inst. 2019. PMID: 30312434 Clinical Trial.
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W; SUCCESS Study Group. Jueckstock J, et al. Among authors: trapp e. BMC Cancer. 2016 Jul 7;16:401. doi: 10.1186/s12885-016-2454-3. BMC Cancer. 2016. PMID: 27387743 Free PMC article. Clinical Trial.
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, Fasching PA, Schneeweiss A, Janni W, Rack BK; SUCCESS Study Group. Schramm A, et al. Among authors: trapp e. Clin Breast Cancer. 2017 Jul;17(4):279-285. doi: 10.1016/j.clbc.2016.11.008. Epub 2017 Jan 10. Clin Breast Cancer. 2017. PMID: 28190761 Clinical Trial.
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P, Andergassen U, Jäger B, Trapp E, Alunni-Fabbroni M, Friedl TW, Hecker N, Lorenz R, Fasching P, Schneeweiss A, Fehm T, Janni W, Rack B. Hepp P, et al. Among authors: trapp e. Anticancer Res. 2016 Sep;36(9):4771-6. doi: 10.21873/anticanres.11034. Anticancer Res. 2016. PMID: 27630326 Clinical Trial.
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W, Friedl TWP; SUCCESS Study Group. Schochter F, et al. Among authors: trapp e. Oncol Res Treat. 2018;41(3):93-98. doi: 10.1159/000485566. Epub 2018 Feb 27. Oncol Res Treat. 2018. PMID: 29490302 Clinical Trial.
LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
Trapp EK, Majunke L, Zill B, Sommer H, Andergassen U, Koch J, Harbeck N, Mahner S, Friedl TWP, Janni W, Rack B, Alunni-Fabbroni M. Trapp EK, et al. Mol Oncol. 2017 Nov;11(11):1508-1526. doi: 10.1002/1878-0261.12111. Epub 2017 Sep 30. Mol Oncol. 2017. PMID: 28700115 Free PMC article.
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A, Friedl TW, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran FA, Wallwiener D, Janni W, Fehm T. Schramm A, et al. Among authors: trapp e. Arch Gynecol Obstet. 2016 Feb;293(2):271-81. doi: 10.1007/s00404-015-3879-7. Epub 2015 Sep 9. Arch Gynecol Obstet. 2016. PMID: 26354331 Clinical Trial.
66 results